Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Symptom severity
Systematic review	83 people Data from 1 RCT	Mean improvement in total Positive and Negative Syndrome Scale (PANSS) scores at endpoint short term with haloperidol (mean modal dose 10.8 mg/day) with olanzapine (mean modal dose 11.6 mg/day) Absolute results not reported	Mean difference 11.2 P = 0.02	Effect size not calculated	olanzapine
Systematic review	83 people Data from 1 RCT	Difference in percentage of people with clinical response short term with haloperidol (mean modal dose 10.8 mg/day) with olanzapine (mean modal dose 11.6 mg/day) Absolute results not reported	Mean difference 38% P = 0.003	Effect size not calculated	olanzapine
Systematic review	83 people Data from 1 RCT	Difference in percentage of people with 20% or greater reduction in BPRS total score short term with haloperidol (mean modal dose 10.8 mg/day) with olanzapine (mean modal dose 11.6 mg/day) Absolute results not reported	Mean difference 23.9% P = 0.03	Effect size not calculated	olanzapine
Systematic review	263 people Data from 1 RCT	Mean improvement in total PANSS scores short term 75.56 to 59.33 with haloperidol (mean modal dose 4.4 mg/day) 75.9 to 55.85 with olanzapine (mean modal dose 9.1 mg/day)	P = 0.58		Not significant
Systematic review	263 people Data from 1 RCT	Difference in percentage of people achieving response short term with haloperidol (mean modal dose 4.4 mg/day) with olanzapine (mean modal dose 9.1 mg/day) Absolute results not reported	Mean difference 7.3% P value not reported
RCT	27 people	Difference in mean PANSS total score 0 to 56 days 72.38 to 56.10 with haloperidol (average daily dose 9.32 mg) 76.14 to 62.00 with olanzapine (average daily dose 12 mg)	P >0.05		Not significant
RCT	35 people	Change from baseline in PANSS positive score endpoint 13.05 to 14.16 with haloperidol (doses 15–20 mg/day) 14.13 to 12.06 with olanzapine (doses 15–20 mg/day)	P = 0.884		Not significant
RCT	35 people	Change from baseline in PANSS negative score endpoint 26.16 to 22.58 with haloperidol (doses 15–20 mg/day) 26.88 to 18.25 with olanzapine (doses 15–20 mg/day)	P = 0.031	Effect size not calculated	olanzapine
RCT	276 people	Change from baseline in PANSS positive score 8 weeks –8.9 with haloperidol (doses 5–20 mg/day) –9.7 with olanzapine (doses 5–20 mg/day)	P = 0.325		Not significant
RCT	276 people	Change from baseline in PANSS positive score 24 weeks –10.2 with haloperidol (doses 5–20 mg/day) –11.5 with olanzapine (doses 5–20 mg/day)	P = 0.128		Not significant
RCT	276 people	Change from baseline in PANSS negative score 8 weeks –7.1 with haloperidol (doses 5–20 mg/day) –8.1 with olanzapine (doses 5–20 mg/day)	P = 0.218		Not significant
RCT	276 people	Change from baseline in PANSS negative score 24 weeks –8.6 with haloperidol (doses 5–20 mg/day) –11.0 with olanzapine (doses 5–20 mg/day)	P = 0.007	Effect size not calculated	olanzapine